U.S. Pharma Stock News

Why Somnigroup International (SGI) is on investors’ radar Somnigroup International (SGI) recently rebranded from Tempur Sealy International, a change that draws attention to how this bedding manufacturer’s shares have behaved after a 3% one day and 8% week decline. See our latest analysis for Somnigroup International. The recent 1 day share price return of 3.05% and 7 day return of 8.49% sit against a 30 day share price decline of 16.94% and a year to date decline of 9.85%, while the 1 year...

CMS Energy (NYSE:CMS) reported strong Q4 2025 results and raised its 2026 EPS guidance. The company introduced a 20-year plan centered on expanding solar and wind capacity. Management highlighted the long-term shift towards renewable energy alongside financial updates. For investors watching NYSE:CMS, these updates come with the stock at $77.16 and a return of 53.7% over the past 5 years. The recent 9.6% gain year to date and 42.6% return over 3 years show how the share price has moved over...

Range Resources Corporation recently reported past fourth-quarter and full-year 2025 results showing higher revenue and net income year-on-year, alongside increased production volumes across natural gas, NGLs and oil, and the Board approved an 11% increase in the quarterly cash dividend to US$0.10 per share, payable on March 27, 2026. The company’s 2026 production guidance of approximately 2.35–2.40 Bcfe per day, with liquids above 30% of output, highlights a growing liquids mix that could...

Tremco, a unit of RPM International (NYSE:RPM), has agreed to acquire Kalzip GmbH. The deal brings Kalzip’s aluminum building envelope systems into RPM’s building solutions portfolio. The acquisition is expected to expand RPM’s reach across Europe, India, and North America. RPM International, through its Tremco segment, focuses on building envelope products such as roofing, waterproofing, and related systems. Adding Kalzip’s metal roofing and façade solutions fits within that core line of...

Omada Health (OMDA) is back in focus after reporting its first GAAP profitable quarter, alongside revenue growth in 2025 and improved margins, while also rolling out its GLP-1 Flex Care program for employers. See our latest analysis for Omada Health. The recent earnings beat, first GAAP profitable quarter and launch of GLP-1 Flex Care have coincided with a 20.6% 1 month share price return. However, the negative 90 day and year to date share price returns suggest momentum has only recently...

If you are wondering whether Corvus Pharmaceuticals' recent share price puts it at a bargain or a stretched level, you are not alone. This article is here to unpack what that current price might mean for value focused investors. The stock has been volatile, with a 7 day return of an 11.7% decline and a 30 day return of a 22.8% decline, set against a year to date return of 115.8% and a 1 year return of 271.6%, plus an increase of more than 7x over 3 years and 381.6% over 5 years. Recent...

In recent days, Essex Property Trust’s fourth-quarter 2025 results came in below expectations while the company’s board approved a 0.8% annual dividend increase, marking its 32nd consecutive year of dividend growth. At the same time, a mix of cautious analyst commentary and industry concerns about below pre-COVID multifamily occupancy levels has sharpened investor focus on how Essex balances income stability with near-term operational challenges. Next, we’ll examine how Essex’s earnings...

Why Denali’s recent earnings and shelf registration matter for shareholders Denali Therapeutics (DNLI) has drawn fresh attention after reporting a wider fourth quarter and full year 2025 loss alongside a new US$200.7 million shelf registration for common stock, raising questions about dilution and funding plans. For the fourth quarter, Denali reported a net loss of US$128.55 million, with basic and diluted loss per share from continuing operations of US$0.73, compared with US$0.67 a year...

Full year 2025 earnings reset the conversation Civitas Resources (CIVI) recently reported full year 2025 results, with revenue of US$4,393 million and net income of US$561 million, both lower than the prior year, putting the stock back under closer investor review. See our latest analysis for Civitas Resources. At a share price of US$27.38, Civitas Resources has seen a 5.0% decline in its 90 day share price return and a 43.4% drop in its 1 year total shareholder return. This suggests momentum...

Q4 earnings and capital moves put MGIC Investment (MTG) in the spotlight MGIC Investment (MTG) drew investor attention after its recent earnings update, which paired flat year over year revenue and an earnings figure in line with expectations, along with a modest post report share price drop. See our latest analysis for MGIC Investment. At a share price of US$26.52, MGIC Investment has seen its short term share price momentum soften, with a year to date share price return of a 9.02% decline...

In late February 2026, Flywire reported fourth-quarter 2025 sales of US$157.54 million and net income of US$0.033 million, alongside full-year 2025 sales of US$623.03 million and net income of US$13.5 million, issued 2026 growth guidance, filed a US$77.86 million ESOP-related shelf registration, and reshaped its technology leadership. The appointment of seasoned payments technologist Patrick Blanc as Chief Technology Officer, coupled with Flywire’s AI-first engineering push and Student...

The Morning Bull - US Market Morning Update Monday, Mar, 9 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 1.3% and Nasdaq 100 futures off roughly 1.5%, as investors react to a jump in borrowing costs and energy prices. The US 10 year Treasury yield is around 4.22%, meaning mortgages, car loans, and corporate borrowing can all stay more expensive for longer, while oil above US$100 keeps pressure on fuel and transport costs. With Middle East...

Dillard’s, Inc. recently reported fourth-quarter and full-year results showing slightly lower sales, revenue and net income compared with the prior year, while its board declared a US$0.30 per-share dividend payable in May 2026. Alongside these results, Dillard’s completed a sizeable share repurchase program and launched the exclusive Amanda Jones Vaughan x Antonio Melani capsule collection across its stores and online. With earnings modestly softer and a fresh exclusive fashion...

Recent coverage of American Superconductor (AMSC) has focused on its shift toward power systems for energy grids and naval technology, where consistent double-digit sales growth and stronger cash generation are drawing fresh investor attention. See our latest analysis for American Superconductor. Even after a sharp 10.2% one day share price decline and a 12.3% year to date share price pullback to about US$27.70, American Superconductor still carries a 57.9% one year total shareholder return...

Why RONN Stock Is On Traders’ Radar RONN (RONN) has drawn attention after sharp recent swings, with returns around 99% over the past week and past 3 months, putting this small zero emission vehicle developer back in focus for speculative investors. See our latest analysis for RONN. That surge in recent share price returns over the past week and past quarter comes after a much tougher stretch, with the 1 year total shareholder return still showing a 50% decline. This highlights how quickly...

Ryan Specialty Holdings (RYAN) is back in focus after reporting 2025 revenue of more than US$3.05b, completing five acquisitions, and launching its three year Empower Program to streamline operations and cut costs. See our latest analysis for Ryan Specialty Holdings. Despite the Empower Program and recent acquisitions getting attention, Ryan Specialty Holdings’ 1 day share price return of 1% and 7 day share price return of 0.9% sit against a 30 day share price decline of 16.4%, a year to date...

If you are wondering whether Bel Fuse shares still offer value after a strong run, this article explains what the current price might be implying about the business. The stock closed at US$172.94 recently, with a 7 day return of an 18.4% decline and a 30 day return of a 16.0% decline, while the 1 year return sits at 119.7% and the 3 year return is very large. These price moves sit against a backdrop of ongoing attention on Bel Fuse within the tech sector, as investors reassess companies that...

If you are wondering whether Microsoft is still fairly priced after its long run as a market heavyweight, looking closely at its current valuation can help you decide how it might fit into your portfolio. The stock last closed at US$408.96, with returns of 2.6% over the past 7 days, 1.9% over the past 30 days, a year-to-date return of a 13.5% decline, and 8.4% over the past year. The 3-year and 5-year returns sit at 64.9% and 81.5% respectively. Recent headlines around Microsoft have focused...

On February 24, 2026, Brady Corporation’s board declared a US$0.245 per-share dividend on Class A common stock, payable April 30, 2026, to shareholders of record as of April 9, 2026. This dividend decision comes alongside multi-year growth in sales, earnings, and free cash flow, underscoring Brady’s capacity to return cash to investors. We’ll now examine how Brady’s dividend declaration, against a backdrop of solid multi-year earnings and cash flow growth, influences its investment...

In a recent filing, Eva Live announced it secured $7 million in growth financing, another step closer to advancing the company’s broader investment narrative.

Recent share performance and business snapshot With no single headline event driving attention to Veris Residential (VRE), the recent share performance itself is the focus, as the stock shows double digit returns over the past month and past 3 months. Veris Residential is a real estate investment trust focused on Class A multifamily properties in the Northeast. It uses a technology enabled, vertically integrated platform to manage, operate, acquire, and develop its portfolio for residents and...

Certara recently highlighted that its Simcyp physiologically-based pharmacokinetic modeling was accepted by the U.S. FDA in place of multiple clinical pharmacology studies to support the new drug application for asciminib (Scemblix®), an allosteric BCR::ABL1 inhibitor for Chronic Myeloid Leukemia. This decade-long modeling effort, which replaced at least ten dedicated clinical studies and informed dosing and drug-interaction decisions, underscores how biosimulation can cut development costs...

What triggered fresh interest in Xeris Biopharma Holdings (XERS)? Xeris Biopharma Holdings (XERS) has drawn fresh attention after reporting fourth quarter and full year 2025 results that moved from loss to profit, paired with new 2026 revenue guidance and a US$40.7 million shelf registration filing. See our latest analysis for Xeris Biopharma Holdings. Despite Xeris Biopharma Holdings posting improved earnings and setting 2026 revenue guidance, recent share price returns have been weak, with...

MarketAxess Holdings Inc. recently appointed William Quan as Chief Technology Officer, tasking him with modernizing its global technology platforms and embedding AI and advanced data capabilities across the business. By bringing in a leader with deep experience in electronic trading and AI-driven platforms from firms like Amazon Web Services, J.P. Morgan, and Deutsche Bank, MarketAxess is signaling a stronger push to enhance its bond-trading technology and product innovation. With William...